Abstract
Dual anti-platelet therapy remains a cornerstone in the management of patients suffering from acute coronary syndromes (ACS). The combination of aspirin and clopidogrel has been shown to result in significant reductions in cardiovascular end points including recurrent infarction and death in several randomised control trial of patients with ACS. However, many patients still experience ischaemic events on the combination of aspirin and clopidogrel. Aspirin is a relatively weak anti platelet agent. Clopidogrel is a pro drug that required activation by hepatic metabolism and hence its onset of action is delayed; there is genetic variation in the clinical response to the drug, the platelet inhibition is irreversible and no intravenous form is available. Consequently new anti-platelet agents have been developed to address the short falls of this combination therapy. This paper discusses existing anti-platelet regimes and focuses on novel antiplatelet agents that are currently under clinical evaluation.
Keywords: Acute coronary syndrome, aspirin, clopidogrel, prasugrel, ticagrelor, cangrelor, elinogrel, vorapaxar, atopaxar
Cardiovascular & Hematological Disorders-Drug Targets
Title: Anti-Platelet Therapy for Acute Coronary Syndrome: A Review of Currently Available Agents and What the Future Holds
Volume: 11 Issue: 2
Author(s): F. A. Syed, J. H.N. Bett and D. L. Walters
Affiliation:
Keywords: Acute coronary syndrome, aspirin, clopidogrel, prasugrel, ticagrelor, cangrelor, elinogrel, vorapaxar, atopaxar
Abstract: Dual anti-platelet therapy remains a cornerstone in the management of patients suffering from acute coronary syndromes (ACS). The combination of aspirin and clopidogrel has been shown to result in significant reductions in cardiovascular end points including recurrent infarction and death in several randomised control trial of patients with ACS. However, many patients still experience ischaemic events on the combination of aspirin and clopidogrel. Aspirin is a relatively weak anti platelet agent. Clopidogrel is a pro drug that required activation by hepatic metabolism and hence its onset of action is delayed; there is genetic variation in the clinical response to the drug, the platelet inhibition is irreversible and no intravenous form is available. Consequently new anti-platelet agents have been developed to address the short falls of this combination therapy. This paper discusses existing anti-platelet regimes and focuses on novel antiplatelet agents that are currently under clinical evaluation.
Export Options
About this article
Cite this article as:
A. Syed F., H.N. Bett J. and L. Walters D., Anti-Platelet Therapy for Acute Coronary Syndrome: A Review of Currently Available Agents and What the Future Holds, Cardiovascular & Hematological Disorders-Drug Targets 2011; 11 (2) . https://dx.doi.org/10.2174/187152911798347007
DOI https://dx.doi.org/10.2174/187152911798347007 |
Print ISSN 1871-529X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4063 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Nanomedicine Based Nanoparticles for Neurological Disorders
Current Medicinal Chemistry Aquaporin Water Channels in Central Nervous System
Current Neurovascular Research Sleep and Antidepressant Treatment
Current Pharmaceutical Design Pulmonary Valve Endocarditis: A Case Report
Infectious Disorders - Drug Targets Integrating Virtual Screening Methods to the Quest for Novel Membrane Protein Ligands
Current Medicinal Chemistry - Central Nervous System Agents Emerging Role of Complement in Ocular Diseases
Current Immunology Reviews (Discontinued) Matrix Metallopropteinases in Heart Failure
Current Topics in Medicinal Chemistry N1-Methylnicotinamide: The Mysterious Anti-aging Actor in Renal Transplantation
Current Pharmaceutical Design Cytokine Storm and Neuropathological Alterations in Patients with Neurological Manifestations of COVID-19
Current Alzheimer Research Catheter Ablation of Lone Atrial Fibrillation
Current Pharmaceutical Design Impact of the Fontan Operation on Organ Systems
Cardiovascular & Hematological Disorders-Drug Targets Living Life to the Fullest: Early Integration of Palliative Care into the Lives of Children with Chronic Complex Conditions
Current Pediatric Reviews Fish Gelatin Hydrolysates as Antioxidant, Antihypertensive, and Antidiabetic: The Plausible Mechanisms
Mini-Reviews in Organic Chemistry Fenofibrate and Telmisartan in the Management of Abdominal Aortic Aneurysm
Current Drug Targets Preface: EDITORIAL COMMENT “Perfect 24-hr Blood Pressure Control” From Morning to Nocturnal Hypertension: Up-To-Date 2015
Current Hypertension Reviews Oxytocin in the Heart Regeneration
Recent Patents on Cardiovascular Drug Discovery Therapeutic Agents for COVID-19: an Overview
Current Drug Therapy The Challenge of Counterfeit Drugs: A Comprehensive Review on Prevalence, Detection and Preventive Measures
Current Drug Safety Disrupted Structural Brain Network in AD and aMCI: A Finding of Long Fiber Degeneration
Current Alzheimer Research The Effect of DPP-4i on Endothelial Function and Arterial Stiffness in Patients with Type 2 Diabetes: A Systematic Review of Randomized Placebo-controlled Trials
Current Pharmaceutical Design